# Paolo A. Ascierto

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/paolo-a-ascierto/

## Facts

| Field | Value |
| --- | --- |
| Citations | 111,178 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 126 |
| i10-index | 675 |
| Last Known Institution | Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" |
| OpenAlex ID | https://openalex.org/A5029398339 |
| ORCID iD | https://orcid.org/0000-0002-8322-475X |
| Works | 1,670 |

## Researcher papers

Showing 12 of 13.

- [Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-melanoma-who-progressed/)
- [Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma/)
- [Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events](https://scholariq.org/papers/society-for-immunotherapy-of-cancer-sitc-clinical-practice-guideline-on-immune/)
- [Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv/)
- [A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable](https://scholariq.org/papers/a-multicenter-study-of-body-mass-index-in-cancer-patients-treated-with-anti-pd-1/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort](https://scholariq.org/papers/nivolumab-monotherapy-and-nivolumab-plus-ipilimumab-in-recurrent-small-cell-lung/)
- [Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus](https://scholariq.org/papers/managing-cancer-patients-during-the-covid-19-pandemic-an-esmo-multidisciplinary/)
- [Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice](https://scholariq.org/papers/integrated-analysis-of-concomitant-medications-and-oncological-outcomes-from-pd/)
- [Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study](https://scholariq.org/papers/clinical-outcomes-of-patients-with-advanced-cancer-and-pre-existing-autoimmune/)
- [Defining the critical hurdles in cancer immunotherapy](https://scholariq.org/papers/defining-the-critical-hurdles-in-cancer-immunotherapy/)
- [Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer](https://scholariq.org/papers/clinical-outcomes-and-toxic-effects-of-single-agent-immune-checkpoint-inhibitors/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"](https://scholariq.org/institutions/istituto-nazionale-tumori-irccs-fondazione-g-pascale/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.